Literature DB >> 11095948

Anisomycin affects both pro- and antiapoptotic mechanisms in PC12 cells.

B Törocsik1, J Szeberényi.   

Abstract

Survival and differentiation of PC12 cells depend on the proper balance between the activities of several mitogen-activated protein kinase (MAPK) pathways. We have previously shown that low, nontoxic doses of anisomycin stimulated these MAPKs as well as the expression of several early-response genes and inhibited NGF-induced neurite formation. In the present work we show that protein synthesis-inhibiting concentrations of anisomycin, in contrast, cause apoptosis of PC12 cells. To try to characterize the apoptosis-inducing mechanisms of anisomycin we compared the signaling effects of subinhibitory and inhibitory drug concentrations. Anisomycin in a nontoxic dosis activates the same MAPK pathways and early-response genes as in protein synthesis inhibiting concentrations. In contrast, while the subinhibitory anisomycin treatment stimulates Akt and induces Bcl-2, two antiapoptotic proteins, the translation-inhibiting concentration of the drug prevents these survival-promoting biochemical events. Anisomycin thus triggers both pro- and antiapoptotic processes in PC12 cells; stimulation of stress-responsive MAPK cascades is not sufficient to mediate apoptotic signaling: the inhibition of key antiapoptotic proteins appears to be more important for PC12 cell death by anisomycin treatment. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095948     DOI: 10.1006/bbrc.2000.3836

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  The role of protein synthesis during the labile phases of memory: revisiting the skepticism.

Authors:  Cristina M Alberini
Journal:  Neurobiol Learn Mem       Date:  2007-10-24       Impact factor: 2.877

2.  Partial Protection of PC12 Cells from Cellular Stress by Low-Dose Sodium Nitroprusside Pre-treatment.

Authors:  Judit Varga; Judit Bátor; Gergő Nádasdi; Zita Árvai; Renáta Schipp; József Szeberényi
Journal:  Cell Mol Neurobiol       Date:  2015-12-01       Impact factor: 5.046

3.  Partial p53-dependence of anisomycin-induced apoptosis in PC12 cells.

Authors:  R Schipp; J Varga; J Bátor; M Vecsernyés; Z Árvai; M Pap; József Szeberényi
Journal:  Mol Cell Biochem       Date:  2017-04-21       Impact factor: 3.396

4.  Intrahippocampal infusions of anisomycin produce amnesia: contribution of increased release of norepinephrine, dopamine, and acetylcholine.

Authors:  Zhenghan Qi; Paul E Gold
Journal:  Learn Mem       Date:  2009-04-29       Impact factor: 2.460

5.  Anisomycin protects cortical neurons from prolonged hypoxia with differential regulation of p38 and ERK.

Authors:  Soon-Sun Hong; Hong Qian; Peng Zhao; Alia Bazzy-Asaad; Ying Xia
Journal:  Brain Res       Date:  2007-03-01       Impact factor: 3.252

6.  Involvement of proteolytic activation of protein kinase R in the apoptosis of PC12 pheochromocytoma cells.

Authors:  Marianna Pap; József Szeberényi
Journal:  Cell Mol Neurobiol       Date:  2007-12-14       Impact factor: 5.046

7.  microRNA let-7c is essential for the anisomycin-elicited apoptosis in Jurkat T cells by linking JNK1/2 to AP-1/STAT1/STAT3 signaling.

Authors:  Zhiwei Zhou; Xijian Lu; Jin Wang; Jia Xiao; Jing Liu; Feiyue Xing
Journal:  Sci Rep       Date:  2016-04-18       Impact factor: 4.379

8.  Temporal decoding of MAP kinase and CREB phosphorylation by selective immediate early gene expression.

Authors:  Takeshi H Saito; Shinsuke Uda; Takaho Tsuchiya; Yu-ichi Ozaki; Shinya Kuroda
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

9.  The extraction of simple relationships in growth factor-specific multiple-input and multiple-output systems in cell-fate decisions by backward elimination PLS regression.

Authors:  Yuki Akimoto; Katsuyuki Yugi; Shinsuke Uda; Takamasa Kudo; Yasunori Komori; Hiroyuki Kubota; Shinya Kuroda
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.